ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations
PD-1-Naïve Patients More Likely To Derive Benefit
Executive Summary
Clinical data released on drugs targeting LAG-3 from BMS, Regeneron, Merck & Co. and Immutep in a variety of cancers.
You may also be interested in...
Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy
The PD-1/LAG-3 combination showed a high response rate in a small number of melanoma patients with prior PD-1 exposure.
The Journey Has Just Begun For LAG-3 Therapeutics
Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.
BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval
The LAG-3 antibody relatlimab, with Opdivo in the fixed-dose combo Opdualag and a $27,389-per-dose price, is the first approved in a new class of checkpoint inhibitors since the anti-PD-1/PD-L1s.